🎉 M&A multiples are live!
Check it out!

Immunovant Valuation Multiples

Discover revenue and EBITDA valuation multiples for Immunovant and similar public comparables like Benevolent AI, Vivoryon Therapeutics, and Julphar.

Immunovant Overview

About Immunovant

Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).


Founded

2018

HQ

United States of America
Employees

207

Website

immunovant.com

Financials

LTM Revenue $0.4M

LTM EBITDA -$427M

EV

$2.2B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Immunovant Financials

Immunovant has a last 12-month revenue of $0.4M and a last 12-month EBITDA of -$427M.

In the most recent fiscal year, Immunovant achieved revenue of n/a and an EBITDA of -$270M.

Immunovant expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Immunovant valuation multiples based on analyst estimates

Immunovant P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$208M -$270M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$157M -$211M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Immunovant Stock Performance

As of April 15, 2025, Immunovant's stock price is $15.

Immunovant has current market cap of $2.6B, and EV of $2.2B.

See Immunovant trading valuation data

Immunovant Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$2.2B $2.6B XXX XXX XXX XXX $-2.83

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Immunovant Valuation Multiples

As of April 15, 2025, Immunovant has market cap of $2.6B and EV of $2.2B.

Immunovant's trades at 5210.3x LTM EV/Revenue multiple, and -5.3x LTM EBITDA.

Analysts estimate Immunovant's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Immunovant and 10K+ public comps

Immunovant Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $2.2B XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -5.8x XXX XXX XXX
P/E -6.8x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -6.5x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Immunovant Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Immunovant Valuation Multiples

Immunovant's NTM/LTM revenue growth is 2620%

Immunovant's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.3M for the same period.

Over next 12 months, Immunovant's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Immunovant's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Immunovant and other 10K+ public comps

Immunovant Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 30% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $1.3M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Immunovant Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Immunovant M&A and Investment Activity

Immunovant acquired  XXX companies to date.

Last acquisition by Immunovant was  XXXXXXXX, XXXXX XXXXX XXXXXX . Immunovant acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Immunovant

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Immunovant

When was Immunovant founded? Immunovant was founded in 2018.
Where is Immunovant headquartered? Immunovant is headquartered in United States of America.
How many employees does Immunovant have? As of today, Immunovant has 207 employees.
Who is the CEO of Immunovant? Immunovant's CEO is Dr. Peter Salzmann, M.B.A.,M.D..
Is Immunovant publicy listed? Yes, Immunovant is a public company listed on NAS.
What is the stock symbol of Immunovant? Immunovant trades under IMVT ticker.
When did Immunovant go public? Immunovant went public in 2019.
Who are competitors of Immunovant? Similar companies to Immunovant include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Immunovant? Immunovant's current market cap is $2.6B
What is the current revenue of Immunovant? Immunovant's last 12-month revenue is $0.4M.
What is the current EBITDA of Immunovant? Immunovant's last 12-month EBITDA is -$427M.
What is the current EV/Revenue multiple of Immunovant? Current revenue multiple of Immunovant is 5210.3x.
What is the current EV/EBITDA multiple of Immunovant? Current EBITDA multiple of Immunovant is -5.3x.
Is Immunovant profitable? Yes, Immunovant is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.